TruDiagnostic is revolutionizing personalized nutrition by integrating biological age data with nutrient levels and predictions of disease risk.

In collaboration with Longevity Technology, TruDiagnostic is set to offer consumers epigenetic test kits designed to track biological age and nutritional health.

Ryan Smith, the founder of TruDiagnostic, believes that DNA methylation testing could surpass traditional blood tests in predicting health outcomes, providing a detailed overview from just a few drops of blood.

Epigenetics, often referred to as the 'software' of DNA, empowers individuals to understand how their lifestyle modifications can affect their biological health and aging process.

The company plans to introduce 'generation explainable plans' that not only report biological age but also clarify the factors influencing it, helping users make informed health improvements.

Smith emphasizes that lifestyle choices play a crucial role in determining biological age, with recent algorithms indicating that lifestyle influences about 60% of aging, compared to 40% attributed to genetics.

The company is also developing tools to assess risks for chronic diseases, including Alzheimer's and metrics for frailty, facilitating proactive health management.

TruDiagnostic's testing range includes TruAge, which analyzes over 75 biomarkers to determine biological age, and TruHealth, which evaluates more than 110 epigenetic biomarkers for nutritional status.

TruDiagnostic's testing can quantify nutrient levels of longevity-associated compounds, such as vitamin D and alpha-ketoglutarate, offering users actionable insights.